GHO Capital, a European specialist healthcare investor, acquired Quotient Clinical, a Nottingham, UK-based provider of outsourced, early-stage drug development services to the pharmaceutical industry.
HSBC Bank plc provided debt financing for the transaction, whose amount was not disclosed.
Led by Mark Egerton, Chief Executive Officer, Quotient Clinical enables pharmaceutical and biotechnology customers to improve research and development productivity and accelerate drug development timelines.
Its Translational Pharmaceutics® platform offers an integrated approach to drug formulation development, “real-time” manufacturing and clinical testing within a single location to reduce development timelines for customers, costs by conserving drug substance through precise dose selection and formulation modification in response to emerging clinical data; and simplify the supply chain for customers.
It provides support to a range of pharmaceutical companies and small-medium sized biotechnology companies.
The company has 52,000 ft2 of integrated operating facilities in Nottingham for pharmaceutical sciences and clinical trials, and a data sciences function based in Edinburgh which includes medical writing, statistics and programming. Quotient’s state-of-the-art facilities are approved to Good Manufacturing Practice (GMP) and Good Clinical Practice (GCP) standards with scalable technologies and processes.
It employs over 280 professionals.